First patient treated with ILB in TIKOMED’s clinical trial for ALS
Viken, November 2nd, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological diseases, announce today that the first patient with Amyotrophic Lateral Sclerosis (ALS) has been treated with the company’s investigational drug ILB, in the on-going clinical trial at Sahlgrenska University Hospital in Gothenburg, Sweden.
Anders Svenson M.D., Chief Medical Officer of TIKOMED, commented, “We are very pleased that our clinical trial, with our investigational drug ILB for the treatment of ALS, is well underway and that the trial’s first patient has successfully completed the four-week treatment period with ILB. We believe this clinical trial, conducted at Sahlgrenska University Hospital, will demonstrate the safety and tolerability of ILB in the treatment of ALS”.
With Dr. Lennart Persson as principal investigator, the clinical trial is conducted at and in collaboration with Sahlgrenska University Hospital in Gothenburg. 15 patients with ALS will receive ILB for a four-week treatment period followed by a three-month, follow-up period.
Anders Kristensson, Chief Executive Officer of TIKOMED, commented, “With ILB we present a potentially new class of drug which can address the underlying causes of neurodegeneration, as seen in a chronic disease such as ALS. We are committed to bringing ILB through our ALS clinical trial program and hopefully one step closer to ALS sufferers battling this fatal disease”.
Tikomed will also be running a phase II ALS study in collaboration with Birmingham University in Birmingham, UK. In this trial, 15 patients with ALS will receive ILB for a ten-week treatment period.